BioVie Announces Abstract Accepted for Presentation at AD/PD 2026

Core Insights - BioVie Inc. announced the acceptance of an abstract for its SUNRISE-PD study on bezisterim (NE3107) for treating Parkinson's Disease at the AD/PD 2026 conference [1][2] Group 1: Study and Results - The abstract titled "Demographics and Baseline Characteristics of Participants in a Study of Bezisterim (NE3107) in Early Parkinson's Disease (SUNRISE-PD)" summarizes initial data from the study, which will be presented as a poster [2] - Topline results from the SUNRISE-PD study are expected in mid-2026, following the enrollment of 60 patients to evaluate bezisterim's efficacy in improving motor and non-motor symptoms in untreated Parkinson's patients [4] Group 2: Drug Mechanism and Applications - Bezisterim (NE3107) is an oral drug that crosses the blood-brain barrier, aiming to reduce inflammation and improve insulin sensitivity without immune suppression, showing potential for various neurological conditions including Parkinson's, Long COVID, and Alzheimer's [3][7] - In previous Phase 2 studies for Parkinson's, patients taking bezisterim with levodopa exhibited better motor control and fewer symptoms compared to those on levodopa alone, with minimal side effects reported [4] Group 3: Other Clinical Trials - The ADDRESS-LC trial is currently enrolling about 200 patients to assess bezisterim's ability to alleviate neurological symptoms associated with Long COVID, with topline data also expected in mid-2026 [5] - BioVie has conducted Phase 2 and Phase 3 trials for Alzheimer's disease, with early results indicating improvements in cognition and biomarkers, warranting further investigation [6] Group 4: Company Overview - BioVie Inc. is a clinical-stage biopharmaceutical company focused on therapies for neurological disorders and advanced liver disease, with bezisterim targeting neuroinflammation and insulin resistance [7] - The company is also advancing BIV201, a treatment for liver disease that has received FDA Orphan and Fast Track designations, and plans to conduct a Phase 3 trial for patients with cirrhosis and ascites [8]